论文部分内容阅读
目的分析急性脑梗死患者应用疏血通注射液联合依达拉奉治疗的临床疗效观察及对患者血清SOD活性和血液流变学的影响。方法选择株洲市中心医院于2013年8月至2014年8月收治的急性脑梗死患者103例,随机分为研究组(n=53)和对照组(n=50)。研究组给予疏血通注射液联合依达拉奉治疗,对照组仅给予依达拉奉治疗。两组疗程均为2周。结果研究组总有效率明显高于对照组(P<0.05);神经功能缺损评分治疗后两组较治疗前下降(P<0.05),而血清SOD活性治疗后两组较治疗前上升(P<0.05);神经功能缺损评分治疗后研究组显著低于对照组(P<0.05),而血清SOD活性治疗后研究组显著高于对照组(P<0.05);红细胞压积、纤维蛋白原以及血浆粘度治疗后研究组较治疗前显著下降(P<0.05);红细胞压积、纤维蛋白原以及血浆粘度治疗后研究组显著低于对照组(P<0.05)。结论急性脑梗死患者应用疏血通注射液联合依达拉奉治疗临床疗效明显,可明显提高患者的血清SOD活性,降低血液流变学指标水平,从而改善血液流变学。
Objective To analyze the clinical effect of Shuxuetong injection combined with edaravone in patients with acute cerebral infarction and its effect on serum SOD activity and hemorheology. Methods 103 patients with acute cerebral infarction who were treated in Zhuzhou Central Hospital between August 2013 and August 2014 were randomly divided into study group (n = 53) and control group (n = 50). The study group was given Shuxuetong injection combined with edaravone treatment, the control group was treated with edaravone only. Two groups of treatment are 2 weeks. Results The total effective rate in the study group was significantly higher than that in the control group (P <0.05). The score of neurological deficit score decreased after treatment in both groups (P <0.05) 0.05). After treatment, the neurological deficit score was significantly lower in the study group than in the control group (P <0.05), while the serum SOD activity in the study group was significantly higher than that in the control group (P <0.05); hematocrit, fibrinogen, The viscosity of the study group after treatment decreased significantly (P <0.05); hematocrit, fibrinogen and plasma viscosity after treatment group was significantly lower than the control group (P <0.05). Conclusion The application of Shuxuetong injection combined with edaravone in patients with acute cerebral infarction significantly improved the clinical efficacy, can significantly improve the patient’s serum SOD activity, reduce the level of hemorheology, thereby improving hemorheology.